Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion

W. J. Mayer, A. Wolf, M. Kernt, D. Kook, A. Kampik, M. Ulbig, C. Haritoglou

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Purpose To evaluate the efficacy and safety of a dexamethasone implant (Ozurdex) alone or in combination with bevacizumab.MethodsSixty-four eyes were prospectively investigated. Group 1 (22 central retinal vein occlusion (CRVO) and 16 branch retinal vein occlusion (BRVO)) was treated with Ozurdex alone, and group 2 (14 CRVO and 12 BRVO) was treated with three consecutive bevacizumab injections followed by Ozurdex. Recurrences were treated with Ozurdex only. Patients were seen preoperatively and thereafter in monthly intervals. The primary end point was best-corrected visual acuity (BCVA) at 12 months.ResultsIn group 1, BCVA improved by 6.6 (±1.7) letters in CRVO and 7.8 (±2.9) in BRVO patients, and in group 2 by 9.8 (±1.0) vs 9.4 (±2.1) letters. A significant difference was only seen between CRVO patients in group 1 and 2 at 12 months (P<0.05). Recurrence after the first Ozurdex injection occurred after 3.8 (CRVO) and 3.5 months (BRVO) in group 1, vs 3.2 and 3.7 months in group 2. Elevated intraocular pressure (>5 mm Hg) was measured in approximately 40% cataract progression requiring surgery in about 50% of eyes after three Ozurdex injections.ConclusionCombined treatment showed slightly better functional outcome for CRVO patients. Increased intraocular pressure and cataract progression was frequent and should be considered when an individual treatment is planned.

Original languageEnglish
Pages (from-to)816-822
Number of pages7
JournalEye (Basingstoke)
Volume27
Issue number7
DOIs
StatePublished - Jul 2013
Externally publishedYes

Keywords

  • Bevacizumab
  • Dexamethasone
  • Macular edema
  • Retinal vein occlusion

Fingerprint

Dive into the research topics of 'Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion'. Together they form a unique fingerprint.

Cite this